PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Covid Pfizer vaccine approved for use next week in UK
  • U.K. regulator, MHRA, authorizes supply of COVID-19 mRNA vaccine for emergency supply under Regulation 174; Companies are ready to deliver the first doses to the U.K. immediately
  • First authorization for a COVID-19 vaccine represents a breakthrough scientific achievement to help combat this devastating pandemic
  • The companies previously signed an agreement to supply a total of 40 million doses to the U.K. with delivery in 2020 and 2021
  • U.S. FDA and EU EMA decisions on authorization are expected in December

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. Pfizer and BioNTech are anticipating further regulatory decisions across the globe in the coming days and weeks and are ready to deliver vaccine doses following potential regulatory authorizations or approvals. The distribution of the vaccine in the U.K. will be prioritized according to the populations identified in guidance from the Joint Committee on Vaccination and Immunisation (JCVI).

“Today’s Emergency Use Authorization in the U.K. marks a historic moment in the fight against COVID-19. This authorization is a goal we have been working toward since we first declared that science will win, and we applaud t…

Read More...
Covid Pfizer vaccine approved for use next week in UK

Articles